Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2010 by Hallym University Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
Hallym University Medical Center
ClinicalTrials.gov Identifier:
NCT01211886
First received: September 29, 2010
Last updated: October 4, 2011
Last verified: September 2010
  Purpose

Admission BNP was a useful marker for diagnosing and predicting type IV cardio-renal syndrome type IV in patients with chronic kidney disease admitted to the ICU for acute heart failure in a retrospective study. Therefore, we aim to prospectively investigate the utility of serum BNP in evaluating the treatment adequacy and predicting future cardiac events in patients with type IV CRS.


Condition
Chronic Kidney Disease
Acute Heart Failure

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Utility of BNP in Patients With Type IV Cardio-renal Syndrome Admitted to the ICU: a Prospective Observational Study

Resource links provided by NLM:


Further study details as provided by Hallym University Medical Center:

Biospecimen Retention:   Samples Without DNA

Serum sample for BNP level


Estimated Enrollment: 83
Study Start Date: September 2010
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with chronic kidney disease admitted to the ICU for acute heart failure (i.e., type IV cardio-renal syndrome)

Criteria

Inclusion Criteria:

  • Adult patients aged > 18 years, Patients with chronic kidney disease (Serum Cr > 2.0, Documented medical history of chronic kidney disease

Exclusion Criteria:

  • Cardiopulmonary resuscitation, Do-not-resuscitate state, Acute kidney injury, ICU stay < 1 day
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Hallym University Medical Center
ClinicalTrials.gov Identifier: NCT01211886     History of Changes
Other Study ID Numbers: f2000tj1
Study First Received: September 29, 2010
Last Updated: October 4, 2011
Health Authority: Korea: Food and Drug Administration

Keywords provided by Hallym University Medical Center:
Brain natriuretic peptide
Cardio-renal syndrome

Additional relevant MeSH terms:
Cardio-Renal Syndrome
Heart Failure
Kidney Diseases
Renal Insufficiency, Chronic
Syndrome
Cardiovascular Diseases
Disease
Heart Diseases
Pathologic Processes
Renal Insufficiency
Urologic Diseases
Natriuretic Peptide, Brain
Cardiovascular Agents
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 22, 2014